Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study

A Sandbaek, S J Griffin, G Rutten, M Davies, R Stolk, K Khunti, K Borch-Johnsen, N J Wareham, T Lauritzen, A Sandbaek, S J Griffin, G Rutten, M Davies, R Stolk, K Khunti, K Borch-Johnsen, N J Wareham, T Lauritzen

Abstract

Aims/hypothesis: The Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION) is a pragmatic randomised controlled trial of the effectiveness of intensified multi-factorial treatment on 5 year cardiovascular morbidity and mortality rates in people with screen-detected type 2 diabetes in the Netherlands, UK and Denmark. This paper describes the baseline characteristics of the study population, their estimated risk of coronary heart disease and the extent to which that risk is potentially modifiable.

Methods: Stepwise screening strategies were performed using risk questionnaires and routine general practice data plus random blood glucose, HbA(1c) and fasting blood glucose measurement. Diabetes was diagnosed using the 1999 World Health Organization criteria and estimated 10 year coronary heart disease risk was calculated using the UK Prospective Diabetes Study risk engine.

Results: Between April 2001 and December 2006, 3,057 people with screen-detected diabetes were recruited to the study (mean age 59.7 years, 58% men) after a stepwise screening programme involving 76,308 people screened in 334 general practices in three countries. Their median estimated 10 year risk of coronary heart disease was 11% in women (interquartile range 7-16%) and 21% (15-30%) in men. There were differences in the distribution of risk factors by country, linked to differences in approaches to screening and the extent to which risk factors had already been detected and treated. The mean HbA(1c) at recruitment was 7.0% (SD 1.6%). Of the people recruited, 73% had a blood pressure > or =140/90 and of these 58% were not on antihypertensive medication. Cholesterol levels were above 5.0 mmol/l in 70% of participants, 91% of whom were not being treated with lipid-lowering drugs.

Conclusions/interpretation: People with type 2 diabetes detected by screening and included in the ADDITION study have a raised and potentially modifiable risk of CHD. ClinicalTrials.gov ID no.: NCT 00237549.

Trial registration: ClinicalTrials.gov NCT00237549.

References

    1. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5:294–315.
    1. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15:815–819. doi: 10.2337/diacare.15.7.815.
    1. Spijkerman AM, Adriaanse MC, Dekker JM, et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care. 2002;25:1784–1789. doi: 10.2337/diacare.25.10.1784.
    1. UK Prospective Diabetes Study 6 Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res. 1990;13:1–11.
    1. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia. 1991;34:877–890. doi: 10.1007/BF00400195.
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. doi: 10.1016/S0140-6736(05)61359-1.
    1. Guillausseau PJ, Massin P, Charles MA, et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabet Med. 1998;15:151–155. doi: 10.1002/(SICI)1096-9136(199802)15:2<151::AID-DIA527>;2-I.
    1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240. doi: 10.2337/diacare.22.2.233.
    1. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 Study. Diabetes Care. 2003;26:2335–2340. doi: 10.2337/diacare.26.8.2335.
    1. Williams DR, Wareham NJ, Brown DC, et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med. 1995;12:30–35.
    1. Glumer C, Yugun M, Griffin S, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia. 2006;49:1536–1544. doi: 10.1007/s00125-006-0248-x.
    1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–1762. doi: 10.1016/S0140-6736(98)04311-6.
    1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.
    1. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010. doi: 10.1016/S0140-6736(02)08090-X.
    1. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–620. doi: 10.2337/diacare.20.4.614.
    1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016. doi: 10.1016/S0140-6736(03)12475-0.
    1. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ. 2001;322:986–988. doi: 10.1136/bmj.322.7292.986.
    1. Borch-Johnsen K, Lauritzen T, Glumer C, Sandbaek A. Screening for type 2 diabetes—should it be now? Diabet Med. 2003;20:175–181. doi: 10.1046/j.1464-5491.2003.00842.x.
    1. Sandbaek A, Lauritzen T, Borch-Johnsen K, Mai K, Christiansen JS. The comparison of venous plasma glucose and whole blood capillary glucose in diagnoses of type 2 diabetes: a population-based screening study. Diabet Med. 2005;22:1173–1177. doi: 10.1111/j.1464-5491.2005.01491.x.
    1. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord. 2000;24(Suppl 3):S6–S11.
    1. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 Study. Diabetes Care. 2004;27:727–733. doi: 10.2337/diacare.27.3.727.
    1. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care. 1997;20:491–496. doi: 10.2337/diacare.20.4.491.
    1. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Low yield of population-based screening for type 2 diabetes in the Netherlands. The ADDITION Netherlands Study. Fam Pract. 2007;24:555–561. doi: 10.1093/fampra/cmm052.
    1. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16:164–171. doi: 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>;2-R.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999.
    1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
    1. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417–1432. doi: 10.1016/0895-4356(93)90142-N.
    1. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) Clin Sci. 2001;101:671–679. doi: 10.1042/CS20000335.
    1. Little RJA, Rubin DB. Statistical analysis with missing data, 2nd edn. New York: Wiley; 2002.
    1. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004;21:238–245. doi: 10.1111/j.1464-5491.2004.01116.x.
    1. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005;22:554–562. doi: 10.1111/j.1464-5491.2005.01494.x.
    1. Bhopal R, Unwin N, White M, et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi and European origin populations: cross sectional study. BMJ. 1999;319:215–220.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe